2024
Overestimation of Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission in Settings of High Community Transmission: Insights From an Informal Settlement Community in Salvador, Brazil
Ticona J, Nery N, Hitchings M, Belitardo E, Fofana M, Dorión M, Victoriano R, Cruz J, Santana J, de Moraes L, Cardoso C, Ribeiro G, Reis M, Khouri R, Costa F, Ko A, Cummings D. Overestimation of Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission in Settings of High Community Transmission: Insights From an Informal Settlement Community in Salvador, Brazil. Open Forum Infectious Diseases 2024, 11: ofae065. PMID: 38516384, PMCID: PMC10957159, DOI: 10.1093/ofid/ofae065.Peer-Reviewed Original ResearchSARS-CoV-2Household transmissionRT-PCR positive casesSecondary attack rateAttack rateSARS-CoV-2 infectionSARS-CoV-2 Omicron variantRisk of infectionCommunity acquisitionTherapeutic optionsCOVID-19-related symptomsCase-finding studyHousehold contactsAcquisition of SARS-CoV-2Increased riskSymptom onsetSecondary infectionBooster vaccinationSevere outcomesBiweekly visitsHighest attack rateRT-PCRInfectionCOVID-19 severe outcomesOmicron BA
2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, Duckwall C, Sosensky P, Di Giuseppe E, Borg R, Fofana M, Ranzani O, Dean N, Andrews J, Croda J, Iwasaki A, Cummings D, Ko A, Hitchings M, Schulz W. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis. PLOS Medicine 2022, 19: e1004136. PMID: 36454733, PMCID: PMC9714718, DOI: 10.1371/journal.pmed.1004136.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionBooster vaccinationPrior infectionOmicron infectionPrimary vaccinationMRNA vaccinationOdds ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPrior SARS-CoV-2 infectionTest-negative case-control analysisYale New Haven Health SystemTest-negative case-control studyCOVID-19 mRNA vaccinationSyndrome coronavirus 2 infectionOmicron variant infectionPrior infection statusCoronavirus 2 infectionCase-control studyCase-control analysisOdds of infectionRisk of infectionRace/ethnicityBooster dosesDate of testNeutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, De los Santos M, Leon P, Breban MI, Billig K, Yildirim I, Pearson C, Downing R, Gagnon E, Muyombwe A, Razeq J, Campbell M, Ko AI, Omer SB, Grubaugh ND, Vermund SH, Iwasaki A. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Medicine 2022, 28: 481-485. PMID: 35051990, PMCID: PMC8938264, DOI: 10.1038/s41591-022-01705-6.Peer-Reviewed Original ResearchConceptsTwo-dose regimenOmicron variantVaccine boosterMRNA vaccinesNeutralization activityDelta variantTwo-dose mRNA vaccinesVirus-specific antibody levelsSARS-CoV-2 Omicron variantMRNA vaccine boosterNeutralization of OmicronNumerous spike mutationsSARS-CoV-2 DeltaPotent neutralization activityInfection-induced immunityCOVID-19 vaccineBNT162b2 boosterBooster vaccinationPrime vaccinationAntibody levelsAntibody titersHumoral immunityImmune escapeInactivated vaccinesVaccine